NASDAQ: ABUSArbutus Biopharma Corp Earnings Dates, Reports, Calls
Arbutus Biopharma earnings were -$76.6M for the trailing 12 months ending Mar 31, 2025, with N/A growth year over year. The latest ABUS earnings report on Mar 31, 2025 announced Q1 2025 earnings of -$24.5M, up 95.7% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, ABUS reported annual earnings of -$69.9M, with -4% growth.
ABUS earnings history
Current Revenue
$6.4M
Current Earnings
-$76.6M
Current Profit Margin
-1,195.9%
ABUS Return on Equity
Current Company
-75.5%
Current Industry
-60.2%
Current Market
31.5%
ABUS's Return on Equity (-75.5%)... subscribe to Premium to read more.
High Return on Equity Performance
ABUS undefined
Current Company
-55.8%
Current Industry
-2.5%
ABUS is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance
Be the first to know when ABUS announces earnings.
ABUS undefined
Current Company
-78.35%
Current Industry
5.8%
ABUS's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance
ABUS vs Biotech Stocks
Arbutus Biopharma Earnings Reports & History FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.